NCT02546297 is a Phase 4 clinical trial of Symbicort in COPD, sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

Who is sponsoring NCT02546297?

NCT02546297 is sponsored by Shanghai Pulmonary Hospital, Shanghai, China.

What drugs are being tested in NCT02546297?

Interventions in NCT02546297: Symbicort, Spiriva.

What condition does NCT02546297 study?

NCT02546297 studies COPD, Bronchiectasis.

Is NCT02546297 still recruiting?

NCT02546297 is currently status unknown. Last updated 1 August 2019.

Last reviewed 2019-08-01 · How we verify

NCT02546297

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Status unknown Phase 4 Last updated 1 August 2019

What this trial tests

Phase 4 trial testing Symbicort in COPD in 90 participants. Status unknown.

Timeline

15 September 2017

Primary endpoint
15 September 2020

1 March 2021

Quick facts

Lead sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	90
Start date	15 September 2017
Primary completion	15 September 2020
Estimated completion	1 March 2021
Sites	1 location across China

Drugs / interventions tested

Symbicort — full drug profile →
Spiriva (TIOTROPIUM BROMIDE) — full drug profile →

Conditions studied

COPD — all drugs for COPD →
Bronchiectasis — all drugs for Bronchiectasis →

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Who can join

18 and older, any sex, with COPD or Bronchiectasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine which treatment is more effective and safer for the patients in COPD C group with bronchiectasis.The research results will help guide physicians to select appropriate individualized treatment and hopefully provide some evidence-based medicine proofs for revising guide.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A systematic review of pharmacotherapeutic clinical trial end-points for bronchiectasis in adults.
Crichton ML, Aliberti S, Chalmers JD. · · 2019 · cited 28× · PMID 30872400 · DOI 10.1183/16000617.0108-2018
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A, Jankowski M, Gross-Sondej I, Storman M, et al · · 2018 · cited 6× · PMID 30141826 · DOI 10.1002/14651858.cd012355.pub2

Verify or expand the search:

Other trials of Symbicort

Trials testing the same drug.

NCT06105671 — U-LABA/ICS Effects on Exercise Performance, Formoterol · NA · completed
NCT03468790 — Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. · Phase 3 · completed
NCT03015259 — Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients · Phase 3 · completed
NCT02157935 — Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Ob · Phase 3 · completed

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Other Shanghai Pulmonary Hospital, Shanghai, China trials

Trials by the same sponsor.

NCT07469488 — A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-M · Phase 4 · not yet recruiting
NCT07494591 — TEAS for Ipsilateral Shoulder Pain After Video-Assisted Thoracoscopic Lung Surgery · NA · not yet recruiting
NCT07517640 — Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial · Phase 2 · not yet recruiting
NCT07393438 — Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Phase 2 · not yet recruiting
NCT07375979 — A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-cente · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02546297 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Pulmonary Hospital, Shanghai, China
Last refreshed: 1 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02546297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing